



THE ECOSYSTEM OF EVIDENCE

Lessons learned in the pandemic
era and future challenges

10th International Conference for EBHC Teachers and Developers
10th Conference of the International Society for EBHC
Taormina, 25th - 28th October 2023

#EBHC2023



When seemingly essential methods don't hold up in a pandemic:

An adaptive approach to a living, rapid review on the SARS-CoV-2 antibody response

Haley Holmer, PhD, MPH

Kate Mackey, MD, MPP

Celia Fiordalisi, MS

Mark Helfand, MD, MS, MPH

Scientific Resource Center

*AHRQ Evidence-based Practice Center
Program*

Nothing to disclose


Co-authors

Kate Mackey, Celia Fiordalisi, Mark Helfand: Nothing to disclose

The authors are responsible for the content of this presentation. It does not necessarily represent the views of the Agency for Healthcare Research and Quality (AHRQ). No statement in this presentation should be construed as an official position of AHRQ or of the US Department of Health and Human Services. This work was funded by AHRQ through the Scientific Resource Center (290-2017-00003-C) contract.



Background



Registe
r
Living
Review
S
HERE!

Background



To describe our novel “SWATH” approach to conducting a living, rapid review on the SARS-CoV-2 antibody response.



- Conducted a living, rapid review on SARS-CoV-2 antibody response

Reviews | June 2021

Antibody Response After SARS-CoV-2 Infection and Implications for Immunity FREE

A Rapid Living Review

Annals of Internal Medicine[®]

Reviews | April 2022

Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection FREE

Reviews | January 2023

Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review FREE

- Demonstrate step-by-step approach to keep review living



June 2020
Version 1



- KQ1:** What is the prevalence, level, and duration of SARS-CoV-2 antibodies among adults infected with or recovered from SARS-CoV-2 infection?
- KQ2:** Do antibodies acquired from SARS-CoV-2 infection confer immunity against reinfection?
- KQ3:** If antibodies to SARS-CoV-2 confer immunity against reinfection, how long does immunity last?

June 2020
Version 1


Time to write the protocol...



KQ1: What is the prevalence, level, and duration of SARS-CoV-2 antibodies among adults infected with or recovered from SARS-CoV-2 infection?

KQ2: Do antibodies acquired from SARS-CoV-2 infection confer immunity against reinfection?

KQ3: If antibodies to SARS-CoV-2 confer immunity against reinfection, how long does immunity last?



Guess what the literature will be like in the future?



Based on what? Seems arbitrary!



Let's think about this before we commit.




June 2020

Version 1: RR Findings

KQ1: What is the prevalence, level, and duration of SARS-CoV-2 antibodies among adults infected with or recovered from SARS-CoV-2 infection?

KQ2: Do antibodies acquired from SARS-CoV-2 infection confer immunity against reinfection?

KQ3: If antibodies to SARS-CoV-2 confer immunity against reinfection, how long does immunity last?



June 2020

Version 1: RR Findings

- KQ1:** What is the prevalence, level, and duration of SARS-CoV-2 antibodies among adults infected with or recovered from SARS-CoV-2 infection?
- KQ2:** Do antibodies acquired from SARS-CoV-2 infection confer immunity against reinfection?
- KQ3:** If antibodies to SARS-CoV-2 confer immunity against reinfection, how long does immunity last?



THE ECOSYSTEM
OF EVIDENCE

Lessons learned in the pandemic
era and future challenges

10th International Conference for EBHC Teachers and Developers
10th Conference of the International Society for EBHC
Taormina, 25th - 28th October 2023
#EBHC2023



GIMBE
EVIDENCE FOR HEALTH

June 2020
Version 1

June 2021 11
Version 2
(Update 1)



KQ1: What is the prevalence, level, and duration of SARS-CoV-2 antibodies among adults infected with or recovered from SARS-CoV-2 infection?

KQ2: Do antibodies acquired from SARS-CoV-2 infection confer immunity against reinfection?

KQ3: If antibodies to SARS-CoV-2 confer immunity against reinfection, how long does immunity last?

POSTPONED



THE ECOSYSTEM
OF EVIDENCE

Lessons learned in the pandemic
era and future challenges

10th International Conference for EBHC Teachers and Developers
10th Conference of the International Society for EBHC
Taormina, 25th - 28th October 2023
#EBHC2023



GIMBE
EVIDENCE FOR HEALTH


June 2020
Version 1

June 2021
Version 2
(Update 1)

Vaccines!



Variants!



KQ1: What is the prevalence, level, and duration...?

- More of the same

KQ1: Not addressed

KQ2: Do antibodies acquired from SARS-CoV-2 infection confer immunity against reinfection?

- No more low-quality studies; Prospective cohort / test-negative case-control studies only?

KQ2: What is the risk of reinfection from SARS-CoV-2 among adults in the general population compared with the risk of infection in people who have never been infected or vaccinated?

KQ3: If antibodies to SARS-CoV-2 confer immunity against reinfection, how long does immunity last?

- Omicron 'era' only!



What concerns were raised about our methods?



Annals
of Internal Medicine®



THE ECOSYSTEM
OF EVIDENCE

Lessons learned in the pandemic
era and future challenges

10th International Conference for EBHC Teachers and Developers
10th Conference of the International Society for EBHC
Taormina, 25th - 28th October 2023
#EBHC2023



GIMBE
EVIDENCE FOR HEALTH

What concerns were raised about our methods?

Annals of Internal Medicine

EDITORIAL

Living, Rapid Reviews in a Rapidly Evolving World

Ann Intern Med. 2023;176:135–136. doi:10.7326/M22-3283

“This living, rapid review demonstrated novel methods to maintain flexibility and relevance in a rapidly changing environment. As interest and experience in living reviews increase, the systematic review field will continue to learn and experiment with different approaches to handle changing questions and methods.”



THE ECOSYSTEM
OF EVIDENCE

Lessons learned in the pandemic
era and future challenges

10th International Conference for EBHC Teachers and Developers
10th Conference of the International Society for EBHC
Taormina, 25th - 28th October 2023
#EBHC2023



GIMBE
EVIDENCE FOR HEALTH

What does “SWATH” stand for?



'SWATH'

- **Systematic Without All The Hassle**
- **Strategic While Also Timely & Helpful**
- **Systematic With All The Headaches**

➤ **Send other suggestions to Mark.Helfand@va.gov**



- This is a story based on our observations over the course of 3 years.
- There was no formal evaluation of our approach.



Conclusions

- Protocol rigidity in systematic reviews is ensconced in our methods for good reason → to reduce bias
- Need research: which protocol changes are more likely to introduce bias? Reduce bias?
- How do we best meet end-user needs in the setting of new disease / evolving context?



Acknowledgements

- Mark Helfand, MD, MS, MPH
- Kate Mackey, MD, MPP
- Celia Fiordalisi, MS
- Charlotte Armstrong, BA
- Devan Kansagara, MD, MCR
- Susan Norris, MD, MPH

